The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir. 19 weeks [clinicaltrials_resource:07682e0fd06d019ff6a1d823726bd58e]

The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir. 19 weeks [clinicaltrials_resource:07682e0fd06d019ff6a1d823726bd58e]

900 mg once a day for 8 weeks
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:07682e0fd06d019ff6a1d823726bd58e
Suppression of Oral HHV8 Shedding With Valganciclovir [clinicaltrials:NCT00194467]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir. 19 weeks [clinicaltrials_resource:07682e0fd06d019ff6a1d823726bd58e]

900 mg once a day for 8 weeks
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:07682e0fd06d019ff6a1d823726bd58e
Bio2RDF identifier
07682e0fd06d019ff6a1d823726bd58e
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:07682e0fd06d019ff6a1d823726bd58e
measure [clinicaltrials_vocabulary:measure]
The reduction in percent days ...... on versus off valganciclovir.
time frame [clinicaltrials_vocabulary:time-frame]
description
900 mg once a day for 8 weeks
identifier
clinicaltrials_resource:07682e0fd06d019ff6a1d823726bd58e
title
The reduction in percent days ...... s off valganciclovir. 19 weeks
@en
inDataset
type
label
The reduction in percent days ...... 82e0fd06d019ff6a1d823726bd58e]
@en